Definitive Healthcare Corp. (NASDAQ:DH) Expected to Announce Quarterly Sales of $48.47 Million

Analysts predict that Definitive Healthcare Corp. (NASDAQ:DHGet Rating) will report $48.47 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Definitive Healthcare’s earnings, with estimates ranging from $48.12 million to $49.11 million. The business is expected to announce its next quarterly earnings results after the market closes on Monday, January 1st.

According to Zacks, analysts expect that Definitive Healthcare will report full-year sales of $220.07 million for the current fiscal year, with estimates ranging from $219.15 million to $220.92 million. For the next year, analysts forecast that the company will post sales of $274.82 million, with estimates ranging from $267.55 million to $281.31 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that that provide coverage for Definitive Healthcare.

Definitive Healthcare (NASDAQ:DHGet Rating) last issued its quarterly earnings data on Wednesday, February 23rd. The company reported $0.04 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.02 by $0.02. The business had revenue of $46.31 million during the quarter, compared to the consensus estimate of $44.78 million.

Several research firms recently issued reports on DH. Barclays reduced their target price on shares of Definitive Healthcare from $26.00 to $23.00 in a report on Thursday, February 24th. Canaccord Genuity Group raised shares of Definitive Healthcare from a “hold” rating to a “buy” rating in a report on Thursday, February 24th. Zacks Investment Research lowered shares of Definitive Healthcare from a “hold” rating to a “sell” rating in a report on Monday. Canaccord Genuity Group raised shares of Definitive Healthcare from a “hold” rating to a “buy” rating and cut their price objective for the company from $46.00 to $28.00 in a report on Thursday, February 24th. Finally, Credit Suisse Group cut their price objective on shares of Definitive Healthcare from $30.00 to $24.00 and set a “neutral” rating for the company in a report on Thursday, February 24th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and six have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $37.00.

Shares of NASDAQ:DH traded down $0.96 during trading on Monday, hitting $24.04. The company’s stock had a trading volume of 376,895 shares, compared to its average volume of 607,027. The company has a 50-day moving average of $23.31 and a 200-day moving average of $28.38. Definitive Healthcare has a 12 month low of $18.15 and a 12 month high of $50.30. The company has a debt-to-equity ratio of 0.18, a current ratio of 3.77 and a quick ratio of 3.77.

In other news, CFO Richard Douglas Booth bought 2,374 shares of the firm’s stock in a transaction that occurred on Thursday, March 3rd. The stock was purchased at an average price of $21.06 per share, with a total value of $49,996.44. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

A number of large investors have recently modified their holdings of the business. M&T Bank Corp acquired a new stake in Definitive Healthcare in the 3rd quarter valued at about $238,000. Victory Capital Management Inc. purchased a new position in Definitive Healthcare during the 3rd quarter worth approximately $203,000. Advisor Group Holdings Inc. purchased a new position in shares of Definitive Healthcare in the 3rd quarter valued at approximately $26,000. TD Asset Management Inc. purchased a new position in shares of Definitive Healthcare in the 3rd quarter valued at approximately $2,697,000. Finally, Jennison Associates LLC purchased a new position in shares of Definitive Healthcare in the 3rd quarter valued at approximately $13,341,000. Institutional investors own 97.34% of the company’s stock.

About Definitive Healthcare (Get Rating)

Definitive Healthcare Corp., together with its subsidiaries, provides healthcare commercial intelligence in the United States. Its solutions provide information on healthcare providers and their activities to help its customers in the area ranging from product development to go-to-market planning, and sales and marketing execution.

Featured Stories

Get a free copy of the Zacks research report on Definitive Healthcare (DH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Definitive Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Definitive Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.